Neovascularisation in tendinopathy: from eradication to stabilisation?

Tero AH Järvinen

Tendinopathy is the most common disorder in sports medicine. Multiple hypotheses have been proposed for the aetiopathogenesis, but many aspects still remain elusive. Microdialysis studies have shown high levels of lactate within tendinosis, even at resting tendons,1 suggesting that hypoxia persists in tendinopathy. The presence of necrotic tenocytes, blocked arteries and anaerobic enzymes within tendinopathy lesions lend further support to the role of hypoxia in the aetiopathogenesis.2 Finally, ‘tendinosis’, the pathognomonic histopathological finding in tendinopathy, is composed of hypoxic, mucoid, hyaline and fibrinoid tissue.2 These tissue types are known to be hypoxia induced.

Tendons are generally poorly vascularised, while certain regions—those most prone to injury—are almost avascular. This can be considered an evolutionary ‘design failure’ that makes tendons susceptible to chronic and acute injuries. As a consequence, healthy tendons have a virtually non-existent tissue turnover throughout adulthood.3 However, somewhat paradoxically, tissue turnover is increased in tendinopathic tendons.3 Given the persisting hypoxia and subsequent anaerobic metabolism,1 2 it comes as no surprise that the enhanced tissue turnover leads to production of poorly organised tissue—tendinosis—in tendinopathy.2

The fundamental survival mechanism of any cell under hypoxia is the activation of hypoxia-inducible factor-1α (HIF-1α),4 a transcription factor that turns on the expression of a large range of genes encoding angiogenic growth factors.4 5 Characteristic features of both tendinopathic and ruptured tendons are elevated expression of HIF-1α and its target genes, the proangiogenic growth factors, such as vascular endothelial growth factor and abundant neovascularisation. (figure 1).5

The neovascularisation has even been proposed as the origin of tendinopathy-related pain,6 and accordingly, its eradication has been used as a therapy for the condition.6 Given that tissue regeneration requires sufficient supply of oxygen and nutrients, the existence of neovascularisation in tendinopathy should be interpreted as a sign of both persisting hypoxia and failed tissue repair attempt.

Although almost completely ignored in sports medicine, it is well-established in the fields of cancer biology and retinopathy that hypoxia-induced neovessels are hyperpermeable.4 In essence, they leak and do not have proper perfusion (figure 1). These hyperpermeable neovessels fail to deliver oxygen and nutrients required for tissue maintenance and possible regeneration. Hyperpermeability also explains the apparent intellectual paradox as to why there is persisting hypoxia within regions of neovascularity.7

As noted, there are some preliminary data to suggest that eradication of neovascularisation has some efficacy in the treatment of tendinopathy. However, from a biological perspective, it is somewhat counterintuitive to assume that eradication of neovessels—those originally induced by cells struggling to survive under hypoxic conditions—could offer a viable long-term solution for tendinopathy. At least, in cancer and retinopathy—conditions with similar vascular changes—antiangiogenic therapies have merely worsened the underlying ischaemia.4 7

A tempting alternative approach is to ‘normalise’ or ‘stabilise’ the neovessels4 (figure 1). These ‘stabilised’ blood vessels with structurally intact vessel walls (lumenisation) and proper perfusion could replenish the supply of oxygen and nutrients and, consequently, enable proper tendon regeneration4 7 (figure 1). Although normalisation of neovascularisation may sound like science fiction, recent discoveries in vascular biology offer new hope, as genes responsible for the stabilisation of neovessels have been

---

**Figure 1** Stabilisation of neovessels in tendinopathy. (A) Tendons respond to hypoxia by secreting angiogenic growth factors that induce the growth of neovessels in tendinopathy. (B) These neovessels are hyperpermeable; they leak and do not have proper perfusion, failing to deliver oxygen and nutrients required for tissue regeneration. Fibrin-rich exudates leak from the neovessels, which results in fibrinoid degeneration, a typical feature of tendinosis in tendinopathy.2 (C) Future therapies should aim to ‘stabilise’ the neovessels, re-establishing the structural integrity of the vessel walls (lumenisation) and consequently enabling proper perfusion that replenishes supply of oxygen and nutrients. Picture adapted from permission from Taylor and Francis Group.9

**Correspondence to** Professor Tero AH Järvinen, Faculty of Medicine and Health Technologies, Tampere University and Department of Orthopedics & Traumatology, Tampere University Hospital, Tampere, Finland; tero.jarvinen@tuni.fi
The proposed hypoxia-induced pathogenesis for tendinopathy might seem at odds with Doppler ultrasound studies that have shown normal oxygen saturation in tendinopathic tendons. However, arterio-venous anastomoses are common in diseased tendons, providing a bypass route for circulation and thus a plausible explanation for the failure to detect reduced oxygen saturation in tendinopathic tendons. In the end, hypoxia is the only possible explanation for the reported high levels of lactate and particularly for the characteristic histopathological findings in tendinopathic tendons.

The quest for new therapies in sports medicine should rely on the discoveries of basic science. The novel model presented proposes a pivotal role for hypoxia in the aetiopathogenesis of tendinopathy. Tendons respond to hypoxia by secreting angiogenic growth factors to induce the growth of neovessels (figure 1). Unfortunately, these neovessels are non-functional by nature, failing to deliver oxygen and nutrients required to reverse the prevailing hypoxia. Stabilisation of neovessels could offer a tempting future therapeutic approach for the treatment of tendinopathy.

To cite Järvinen TAH. Br J Sports Med 2020;54:1–2. Accepted 16 September 2019 Published Online First 8 October 2019 Br J Sports Med 2020;54:1–2. doi:10.1136/bjsports-2019-100608

ORCID iD
Tero AH Järvinen http://orcid.org/0000-0002-4027-1759

REFERENCES
1. Alfredson H, Bjur D, Thorsen K, et al. High intratendinous lactate levels in painful chronic Achilles tendinosis. An investigation using microdialysis technique. J Orthop Res. 2002;20:934–8.
2. Järvinen M, Jossa L, Kannus P, et al. Histopathological findings in chronic tendon disorders. Scand J Med Sci Sports. 1997;7:86–95.
3. Heinemeier KM, Schjerling P, Øhlenschlæger TF, et al. Carbon-14 bomb pulse dating shows that tendinopathy is preceded by years of abnormally high collagen turnover. Faseb J. 2018;32:4763–75.
4. McIntyre A, Harris AL. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med. 2015;7:368–79.
5. Schneider M, Angele P, Järvinen TAH, et al. Rescue plan for Achilles: therapeutics steering the fate and functions of stem cells in tendon wound healing. Adv Drug Deliv Rev. 2018;129:352–75.
6. Pufe T, Petersen WI, Mentelein R, et al. The role of vasculature and angiogenesis for the pathogenesis of degenerative tendons disease. Scand J Med Sci Sports. 2005;15:211–22.
7. Li F, Sawada J, Komatsu M, R-Ras-Akt axis induces endothelial lumenogenesis and regulates the patency of regenerating vasculature. Nat Commun. 2017;8:1720.
8. Knobloch K, Grasemann R, Spies M, et al. Midportion Achilles tendon microcirculation after intermittent combined cryotherapy and compression compared with cryotherapy alone. Am J Sports Med. 2008;36:2128–38.
9. Sawada J, Komatsu M. Normalization of tumor vasculature by R-Ras. Cell Cycle. 2012;11:4285–6.